https://www.selleckchem.com/products/sis17.html
Discrepancies were found for the initial combination therapy scenario. CONCLUSION Since EMA and FDA rely on similar conceptional models when approving FDCs, the reasons behind this general disparity are not clear, but may be found in the lack of evidence from the registration studies. Sponsors and health authorities should work collaboratively on closing that gap.The use of real-world data and real-world evidence to inform health care decisions is increasing. Yet, the variable quality of these data and the lack of widely-accepted criteria
Like
Comment
Share
